Corcept Therapeutics (CORT) Total Current Liabilities (2010 - 2026)

Corcept Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $149.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 4.28% year-over-year to $149.2 million; the TTM figure through Mar 2026 stood at $149.2 million (up 4.28% YoY), while the FY2025 annual figure was $166.1 million, up 17.98% from the prior year.
• Total Current Liabilities came in at $149.2 million for Q1 2026 at Corcept Therapeutics, down from $166.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $172.3 million in Q3 2025 to a low of $49.1 million in Q2 2022.
• A 5-year average of $110.0 million and a median of $104.5 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 129.65% in 2023 and climbed 3.56% in 2024, its largest moves.
• Corcept Therapeutics' Total Current Liabilities stood at $72.5 million in 2022, then jumped by 44.16% to $104.5 million in 2023, then surged by 34.7% to $140.8 million in 2024, then climbed by 17.98% to $166.1 million in 2025, then fell by 10.18% to $149.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $149.2 million, $166.1 million, and $172.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison